Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus PENTACEF.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic